First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 755 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? April 27, 2021 School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... February 17, 2020 A career forged in team science March 10, 2023 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... February 18, 2021 Load more HOT NEWS Breast Cancer Patient Credits Persistent Commercial Messaging for Saving Her Life Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected Cancer Does Not Affect All People Equally: An Expert Q&A on...
